# DESCRIPTION

## FIELD OF THE INVENTION

- define CD6-ALCAM pathway inhibitors

## BACKGROUND OF THE INVENTION

- describe inflammatory and autoimmune diseases
- discuss lupus and lupus nephritis
- highlight limitations of current treatments

## SUMMARY OF THE INVENTION

- introduce CD6-ALCAM pathway inhibition
- describe methods for treating lupus nephritis
- describe methods for treating inflammatory or autoimmune diseases
- determine soluble CD6 and/or ALCAM protein levels
- administer CD6-ALCAM pathway inhibitor based on protein levels
- describe methods for identifying subjects with CD6-ALCAM pathway inhibitor-sensitive disease
- describe methods for predicting prognosis of subjects with lupus nephritis
- describe methods for predicting prognosis of subjects with inflammatory or autoimmune diseases
- describe methods for determining active lupus nephritis
- describe methods for determining active inflammatory or autoimmune disease
- describe administration of CD6-ALCAM pathway inhibitor and additional therapeutic agents

## BRIEF DESCRIPTION OF THE SEQUENCES

- list SEQ ID NOs for EQ001 VH and VK sequences and CDRs

## DETAILED DESCRIPTION OF THE INVENTION

### General Methods

- describe conventional methods of molecular biology and recombinant DNA techniques

### Definitions

- define technical and scientific terms used in the invention
- define articles and conjunctions used in the invention
- define terms related to administering and binding partners
- define terms related to antibodies and immunoglobulins
- define terms related to effective amounts and therapeutic doses
- define miscellaneous terms used in the invention

### Overview

- introduce inflammatory/autoimmune diseases
- motivate soluble CD6/ALCAM as biomarkers
- describe CD6/ALCAM pathway in T-cell regulation
- introduce CD6-ALCAM pathway
- discuss prior art on CD6 antibodies
- motivate need for biomarker strategy
- describe method for identifying subjects with inflammatory/autoimmune disease
- describe method for treating subjects with inflammatory/autoimmune disease
- describe method for using CD6-ALCAM pathway inhibitor to treat subjects
- describe method for predicting prognosis of subjects with inflammatory/autoimmune disease
- describe method for determining whether subject has active inflammatory/autoimmune disease
- describe method for determining whether subject has transitioned from inactive to active disease
- describe administration of CD6-ALCAM pathway inhibitor

### Inflammatory or Autoimmune Diseases

- describe diseases

### Samples

- describe sample sources
- describe sample collection and monitoring

### Detection Methods

- describe detection of soluble CD6 and ALCAM
- describe detection methods
- describe qualitative and quantitative detection
- describe threshold value determination
- describe detection of CD6 and ALCAM polynucleotides

### Thresholds

- describe threshold determination methods

### CD6-ALCAM Pathway Inhibitors

- introduce CD6-ALCAM pathway inhibitors
- define anti-CD6 antibody
- describe EQ001
- summarize anti-CD6 antibody characteristics
- describe pharmaceutical compositions
- outline combination therapies
- describe administration methods
- discuss formulations
- outline sustained-release preparations
- describe dosage regimens
- introduce kits for performing methods

## EXAMPLES

- illustrate ELISA-based detection of soluble CD6 and soluble ALCAM protein in urine of subjects with lupus nephritis

### ELISA-Based Detection of Soluble CD6 and Soluble ALCAM Protein in Urine of Subjects with Lupus Nephritis

- describe sample collection and treatment
- compare soluble CD6 and soluble ALCAM levels across cohorts

### CD6 and ALCAM Expression are Significantly Elevated in Human Renal Tissue Biopsies and are Detectable in Urine Cells from Lupus Nephritis (LN) Patients

- analyze RNASeq data to confirm elevated CD6 and ALCAM expression in LN patients
- demonstrate correlation between urinary ALCAM levels and disease activity

### High Levels of Soluble CD6 and Soluble ALCAM Protein in Urine as a Biomarker for Sensitivity to Treatment with EQ001

- evaluate soluble CD6 and soluble ALCAM as biomarkers for treatment response

### Treatment of Spontaneous SLE/Lupis Nephritis (LN) with CD6 Blockade

- confirm overexpression of CD6 and ALCAM in MRL/MpJ-Faslpr/2J mouse model
- demonstrate therapeutic effect of anti-CD6 antibody in reducing kidney damage and mortality
- show improvement in skin disease and lymphoproliferative phenotype

### Example 5

- introduce NTN model of LN
- describe treatment with CD6 blockade
- present results of treatment on kidney function and immune cell infiltration
- examine CD6-ALCAM pathway in NZB/W F1 and B6.Sle1yaa models of SLE
- test CD6 blockade in NZB/W F1 model

